All News
Improving Understanding in SSc
2026 EULAR Press Release
Systemic sclerosis is a rare connective tissue disorder characterised by autoimmune features with vascular manifestations, causing fibrosis of the skin and internal organs. EULAR is focused on systemic sclerosis as the rheumatic disease with the highest morbidity and mortality. New data presented at the EULAR 2026 Congress underscore key complications, and offer hope for a possible new therapeutic strategy.
Read Article
Immune Dimming or Immune Reset in RA: How Far Should We Go?
CD19-directed CAR T-cell therapy has rapidly moved into autoimmune disease, driven in large part by striking reports in SLE, where sustained drug-free remission has raised the possibility of a true immune reset. In RA, where multiple effective therapeutic classes already exist, the relevance of such deep immune interventions remains uncertain.
Read Article
All content is independently chosen and produced by the RheumNow faculty. Our expanded #EULAR2026 coverage is made possible by support from Bristol Myers Squibb and UCB.
Dr. John Cush RheumNow ( View Tweet)
#EULAR2026 LB0003 CAR-T is not scalable. In a Phase 2a of off-the-shelf AB-101 allogenic NK + low dose conditioning (Cyclo & Flud) + Rituximab: preliminary efficacy & safety profile in severe-refractory RA (N=15), SjD (11), SSc (5). Longer FU & Comparator is needed @RheumNow https://t.co/gQniufREQC
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2026 LB0004 First BiTE, now TriTE! Tri-specific CC312 CD19/CD3/CD28 (i.e. CD28 co-stimulates Tcell activation) showed deep Bcell depletion, early efficacy & safety in 10 #SLE patients up to 52WKs. Promising but longer FU needed to see if repeat dosing needed @RheumNow https://t.co/6Lbm9LYJrY
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
JASMINE-SLE: Proof of concept study on
Nipocalimab for SLE
SRI-4 met at wk 24 for the 15 mg/kg q2w dose va. PBO
Improvement of SRI-4 composite & LLDAS at wk 52
LB0007 @RheumNow #EULAR2026 https://t.co/0wzHyid3dy
Links:
sheila RHEUMarampa ( View Tweet)
#EULAR2026 LB0005 More promising news in #PMR. Phase 3 RCT of Baricitinib + GC Taper in N=46:
Part 1: BARI vs PBO 65% vs 17% GC-Free Remission at WK16
2: PBO-BARI improved response 17% to 65% at WK28
3: Lower remission rate in those stopped BARI vs continued at WK44 @RheumNow https://t.co/D77aHcACJE
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Baricitinib did not demonstrate non-inferiority w/ TNFi for first VTE in the RA-BRIDGE and RA-BRANCH trials.
Identifying high-risk pts and individualizing tx is paramount.
LB0009 @RheumNow #EULAR2026 https://t.co/MSiBq0FnEq
Links:
sheila RHEUMarampa ( View Tweet)
Abstr LB0009
Baricitinib vs TNFi in RA patients enriched for VTE risk. 3,640 patients. 3.7 years median follow-up.
VTE: HR 1.61 (95% CI 0.97–2.66)
non-inferiority not demonstrated
MACE: HR 1.06 no cardiovascular excess
Serious infections: HR 1.32 (p<0.05)
@RheumNow https://t.co/NSNRJi9B4r
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Abstr LB0009
Baricitinib vs TNFi in VTE-enriched RA. 3,640 patients. 3.7 years.
Safety endpoints
VTE HR 1.61 non inferiority not met
Serious infections HR 1.32 (p<0.05)
MACE HR 1.06 reassuring
@RheumNow #EULAR2026 https://t.co/nR6TMowlYS
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#EULAR2026 Updated recommendations on the management of PMR &LVV.
A pleasure to have been part of this huge piece of work, covering 3 distinct conditions, and both diagnosis & management principles.
Watch this space for full guideline coming soon!
#EULAR2026
@RheumNow https://t.co/CUvaQVSU8k
Links:
Mrinalini Dey DrMiniDey ( View Tweet)
#EULAR2026 LB0006 Beyond conventional immunosuppressant, a multicentre RCT (N=145) in China showed mTOR-i Sirolimus + SOC met primary endpoint (SRI-4) vs PBO + SOC in #SLE. Favourable safety. Frequent AE: high cholesterol & low WCC. Unclear position in treatment pathway @RheumNow https://t.co/OiFp06467v
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
5 top abstracts in #Myositis @eular_org
1 #Nailfold #capillaries as an early marker of #IIM Rx
2 #brepocitinib +RCT #DM
3 & rapid skin improvement #CLASI
4 #Ab may help #IBM but neg primary endpoint
5 #criteria for #antisynthetase
#EULAR2026 @RheumNow
OP0168, 0166, 0164 POS264
Janet Pope Janetbirdope ( View Tweet)
Top 5 abst in #SjD
#anifrolumab +RCT
#ianalumab LTE Rx sustained
#telitatacept +LTE
#iana improves u/s parotids
#TYK2 sig in#SjD
OP0002, 0126, 127, 160 POS0284
#EULARbest #EULAR2026
@RheumNow @eular_org
Janet Pope Janetbirdope ( View Tweet)
#EULAR2026 LB0007 Phase 2 RCT of Nipocalimab, an FcRn-i in moderate-to-severe #SLE, with mandatory GC taper =<7.5mg/d by WK16: met primary endpoint at WK24 (SRI-4) vs PBO. Effect size better in Ab+, Ab-High & IFN-High. 23% had IgG<3 at WK58 but SIE. Phase 3 is underway @RheumNow https://t.co/EpgNOHcEqC
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Do you target #DORIS / remission in #SLE pts
#EULAR2026 @RheumNow @eular_org
Janet Pope Janetbirdope ( View Tweet)
Aiming for #DORIS #SLE #remission
Or #LLDAS in #SLE
Related to ⬆️survival
#deep outcome in RCTs
➡️archived in #deucravacitinib ph2 #LTE
&
ph3 #dapirolizumab & #obintuzimab
-achieved in #CAR-T trials in #lupus
POS0683, 1364, 0695, OP0338
& several 🚗 T abst
#EULAR2026 @RheumNow
Janet Pope Janetbirdope ( View Tweet)
Do GLP-1 agonists achieve meaningful weight loss in patients with RMDs?
RISE registry
Retrospective
N=60,206
Tirzepatide: lost 8%
Semaglutide: list 6%
At 12 months
PsA had the highest usage
OP0112 #EULAR2026 @RheumNow https://t.co/P3CTgiwqCr
Nelly ZIADE 🍀 Nellziade ( View Tweet)
BARI vs TNFi in VTE-enriched #RA pts (RA-BRIDGE + RA-BRANCH, n=3,640, ~3.7 yrs follow-up): VTE non-inferiority not met (HR 1.61, CI 0.97–2.66).
But absolute rates low (2.5% vs 1.7%) and MACE was similar (HR 1.06). Serious infections ↑ with BARI. @RheumNow #EULAR2026 LB0009
Jiha Lee JihaRheum ( View Tweet)
What drives progression to difficult-to-treat RA?
20-year cohort 675pts
-18.8% developed D2T RA
-Younger age, higher HAQ & prior steroid exposure asso w/ D2T RA
-Earlier b/tsDMARD initiation protective
-No diff TNFi vs non-TNFi first-line strategy
Disease severity and https://t.co/SJDv9HCbLv
Aurelie Najm AurelieRheumo ( View Tweet)
